CRISPR nuclease free to use for all R&D Purposes
With a name inspired by the biological diversity found on the island of Madagascar, MADzymes have improved features such as different PAM recognition sequences, different cut efficiencies, reduced sizes, and different enzyme kinetics.
By developing and broadly releasing these enzymes, Inscripta strives to promote widespread exploration and adoption of CRISPR tools in both academic and commercial settings.
Inscripta has now released the DNA sequence of a first enzyme, MAD7, from its nuclease discovery and engineering platform, that is royalty-free for all R&D use.
MAD7 gene editing systems were recently patented, and have been shown to be effective in both microbial and mammalian systems.
MAD7 activity in mammalian cells
While MAD7 has shown robust editing activities in both prokaryotic and eukaryotic microbes, it has also been shown to have DNA editing activity in mammalian cells.
Initial experiments in HEK293T cells show that the MAD7 is able to be expressed as an active protein in mammalian cells, and when combined with synthetic guide RNAs, can edit different genes at multiple loci.